Skip to main content
Erschienen in: Techniques in Coloproctology 3/2014

01.03.2014 | Short Communication

Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors

verfasst von: M. Pedroni, C. Di Gregorio, L. Cortesi, L. Reggiani Bonetti, G. Magnani, M. L. Simone, V. Medici, C. Priore Oliva, M. Marino, M. Ponz de Leon

Erschienen in: Techniques in Coloproctology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Germline mutations in BRCA1 and BRCA2 genes predispose to hereditary breast cancer, whereas carriers of mutations in any of the mismatch repair genes (MMR; hMLH1, hMSH2, hMSH6, hPMS2) are highly susceptible to Lynch syndrome. In the present study, we describe a woman affected by unilateral breast cancer at the age of 35 years. After 4 years, during the follow-up she developed synchronous (and asymptomatic) endometrial cancer, ovarian carcinoma and renal clear cell carcinoma. After 7 years (at age 46), the patient developed an infiltrating carcinoma of the contralateral breast and died in a few months of metastatic disease. Initial investigations led to the detection of a constitutional mutation in the BRCA1 gene. The extended genealogical tree disclosed a suspected history of colorectal carcinoma in the maternal branch. Endometrial cancer of the proband was investigated for microsatellite instability (MSI) and immunohistochemical expression of MLH1, MSH2 and MSH6 proteins. An high MSI status and lack of expression of MLH1 protein were detected. hMLH1 gene sequencing revealed the presence of a constitutional mutation, which was also found in the mother of the proband. Loss of the wild-type hMLH1 allele was detected in both breast tumors, thus suggesting that the MMR defect contributed to the development of the breast cancer.
Literatur
1.
Zurück zum Zitat Boyd J, Rubin SC (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196–206PubMedCrossRef Boyd J, Rubin SC (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196–206PubMedCrossRef
2.
Zurück zum Zitat Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324PubMedCrossRef Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324PubMedCrossRef
3.
Zurück zum Zitat Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:352–357CrossRef Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:352–357CrossRef
4.
Zurück zum Zitat Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCentralPubMedCrossRef Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef
6.
Zurück zum Zitat Barrow E, Alduaij W, Robinson L et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74:233–242PubMedCrossRef Barrow E, Alduaij W, Robinson L et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74:233–242PubMedCrossRef
7.
Zurück zum Zitat Barrow E, Robinson L, Alduaij W et al (2009) Cumulative life incidence of extracolonic cancer in Lynch syndrome: a of 121 families with proven mutations. Clin Genet 75:141–149PubMedCrossRef Barrow E, Robinson L, Alduaij W et al (2009) Cumulative life incidence of extracolonic cancer in Lynch syndrome: a of 121 families with proven mutations. Clin Genet 75:141–149PubMedCrossRef
8.
Zurück zum Zitat Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18PubMedCentralPubMedCrossRef Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary non polyposis colorectal cancer: an update review. Gastroenterology 104:1535–1549PubMed Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary non polyposis colorectal cancer: an update review. Gastroenterology 104:1535–1549PubMed
10.
Zurück zum Zitat Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117PubMedCrossRef Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117PubMedCrossRef
11.
Zurück zum Zitat Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P (2013) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch Syndrome. Dtsch Arztebl Int 110:32–38PubMedCentralPubMed Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P (2013) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch Syndrome. Dtsch Arztebl Int 110:32–38PubMedCentralPubMed
12.
Zurück zum Zitat Borg A, Isola J, Chen J et al (2000) Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 85:796–800PubMedCrossRef Borg A, Isola J, Chen J et al (2000) Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 85:796–800PubMedCrossRef
13.
14.
Zurück zum Zitat Kast K, Neuhann TM, Gorgens H et al (2012) Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. BMC Cancer 12:531PubMedCentralPubMedCrossRef Kast K, Neuhann TM, Gorgens H et al (2012) Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. BMC Cancer 12:531PubMedCentralPubMedCrossRef
15.
16.
Zurück zum Zitat Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252PubMedCrossRef Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252PubMedCrossRef
17.
Zurück zum Zitat Findeisen P, Kloor M, Merx S et al (2005) T25 repeat in the 3′untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 65:8072–8078PubMedCrossRef Findeisen P, Kloor M, Merx S et al (2005) T25 repeat in the 3′untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 65:8072–8078PubMedCrossRef
18.
Zurück zum Zitat Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM (2001) Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98:5134–5139PubMedCentralPubMedCrossRef Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM (2001) Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98:5134–5139PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Kurzawski G, Suchy J, Kladny J et al (2002) Germline MSH2 and MLH1 mutation spectrum in HNPCC families from Poland and the Baltic States. J Med Genet 39:E65PubMedCentralPubMedCrossRef Kurzawski G, Suchy J, Kladny J et al (2002) Germline MSH2 and MLH1 mutation spectrum in HNPCC families from Poland and the Baltic States. J Med Genet 39:E65PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Bonadona V, Bonaïti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304–2310PubMedCrossRef Bonadona V, Bonaïti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304–2310PubMedCrossRef
21.
Zurück zum Zitat Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 68:1533–1535PubMedCentralPubMedCrossRef Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 68:1533–1535PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Win AK, Young JP, Lindor NM et al (1012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. Clin Oncol 30:958–964CrossRef Win AK, Young JP, Lindor NM et al (1012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. Clin Oncol 30:958–964CrossRef
23.
Zurück zum Zitat Jensen UB, Sunde L, Timshel S et al (2010) Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 120:777–782PubMedCrossRef Jensen UB, Sunde L, Timshel S et al (2010) Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 120:777–782PubMedCrossRef
24.
Zurück zum Zitat Buerki N, Gautier L, Kovac M et al (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Gene Chromosome Cancer 51:83–91CrossRef Buerki N, Gautier L, Kovac M et al (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Gene Chromosome Cancer 51:83–91CrossRef
Metadaten
Titel
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors
verfasst von
M. Pedroni
C. Di Gregorio
L. Cortesi
L. Reggiani Bonetti
G. Magnani
M. L. Simone
V. Medici
C. Priore Oliva
M. Marino
M. Ponz de Leon
Publikationsdatum
01.03.2014
Verlag
Springer Milan
Erschienen in
Techniques in Coloproctology / Ausgabe 3/2014
Print ISSN: 1123-6337
Elektronische ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-013-1030-y

Weitere Artikel der Ausgabe 3/2014

Techniques in Coloproctology 3/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.